Annual EBIT
-$163.00 K
+$41.80 M+99.61%
December 31, 2023
Summary
- As of February 7, 2025, AQST annual earnings before interest & taxes is -$163.00 thousand, with the most recent change of +$41.80 million (+99.61%) on December 31, 2023.
- During the last 3 years, AQST annual EBIT has risen by +$42.60 million (+99.62%).
- AQST annual EBIT is now at all-time high.
Performance
AQST EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$7.31 M
-$8.76 M-604.21%
September 30, 2024
Summary
- As of February 7, 2025, AQST quarterly earnings before interest & taxes is -$7.31 million, with the most recent change of -$8.76 million (-604.21%) on September 30, 2024.
- Over the past year, AQST quarterly EBIT has dropped by -$6.45 million (-747.16%).
- AQST quarterly EBIT is now -170.16% below its all-time high of $10.42 million, reached on September 30, 2017.
Performance
AQST Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$19.26 M
-$6.45 M-50.31%
September 30, 2024
Summary
- As of February 7, 2025, AQST TTM earnings before interest & taxes is -$19.26 million, with the most recent change of -$6.45 million (-50.31%) on September 30, 2024.
- Over the past year, AQST TTM EBIT has dropped by -$13.23 million (-219.15%).
- AQST TTM EBIT is now -381.88% below its all-time high of $6.83 million, reached on September 30, 2017.
Performance
AQST TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
AQST EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +99.6% | -747.2% | -219.2% |
| 3 y3 years | +99.6% | -747.2% | -219.2% |
| 5 y5 years | +99.7% | -747.2% | -219.2% |
AQST EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +99.7% | -176.5% | +71.2% | <-9999.0% | +66.0% |
| 5 y | 5-year | at high | +99.7% | -176.5% | +71.2% | <-9999.0% | +66.7% |
| alltime | all time | at high | +99.7% | -170.2% | +78.8% | -381.9% | +73.4% |
Aquestive Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$7.31 M(-604.2%) | -$19.26 M(+50.3%) |
| Jun 2024 | - | $1.45 M(-116.8%) | -$12.82 M(-30.1%) |
| Mar 2024 | - | -$8.63 M(+80.7%) | -$18.35 M(>+9900.0%) |
| Dec 2023 | -$163.00 K(-99.6%) | -$4.78 M(+453.3%) | -$163.00 K(-97.3%) |
| Sep 2023 | - | -$863.00 K(-78.8%) | -$6.04 M(-57.0%) |
| Jun 2023 | - | -$4.08 M(-142.7%) | -$14.02 M(-38.2%) |
| Mar 2023 | - | $9.55 M(-189.7%) | -$22.67 M(-46.0%) |
| Dec 2022 | -$41.97 M(-12.7%) | -$10.65 M(+20.3%) | -$41.96 M(-26.0%) |
| Sep 2022 | - | -$8.85 M(-30.5%) | -$56.67 M(+1.6%) |
| Jun 2022 | - | -$12.73 M(+30.7%) | -$55.79 M(+13.4%) |
| Mar 2022 | - | -$9.74 M(-61.6%) | -$49.21 M(+2.5%) |
| Dec 2021 | -$48.08 M(+12.4%) | -$25.36 M(+218.2%) | -$47.99 M(+25.4%) |
| Sep 2021 | - | -$7.97 M(+29.7%) | -$38.28 M(-13.2%) |
| Jun 2021 | - | -$6.14 M(-27.9%) | -$44.08 M(+17.5%) |
| Mar 2021 | - | -$8.53 M(-45.5%) | -$37.53 M(-12.2%) |
| Dec 2020 | -$42.76 M | -$15.64 M(+13.6%) | -$42.76 M(+15.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$13.77 M(-3434.9%) | -$36.95 M(-5.1%) |
| Jun 2020 | - | $413.00 K(-103.0%) | -$38.94 M(-32.7%) |
| Mar 2020 | - | -$13.76 M(+39.9%) | -$57.89 M(+1.7%) |
| Dec 2019 | -$56.93 M(+6.1%) | -$9.83 M(-37.6%) | -$56.93 M(-3.7%) |
| Sep 2019 | - | -$15.76 M(-15.0%) | -$59.14 M(+4.7%) |
| Jun 2019 | - | -$18.54 M(+44.8%) | -$56.48 M(-22.1%) |
| Mar 2019 | - | -$12.80 M(+6.3%) | -$72.51 M(+35.1%) |
| Dec 2018 | -$53.66 M(+4241.8%) | -$12.04 M(-8.1%) | -$53.69 M(+8.0%) |
| Sep 2018 | - | -$13.11 M(-62.1%) | -$49.72 M(+89.8%) |
| Jun 2018 | - | -$34.57 M(-673.6%) | -$26.19 M(-691.3%) |
| Mar 2018 | - | $6.03 M(-174.7%) | $4.43 M(-458.3%) |
| Dec 2017 | -$1.24 M(-64.3%) | -$8.07 M(-177.4%) | -$1.24 M(-118.1%) |
| Sep 2017 | - | $10.42 M(-364.0%) | $6.83 M(-290.5%) |
| Jun 2017 | - | -$3.95 M(-1193.6%) | -$3.59 M(-1093.6%) |
| Mar 2017 | - | $361.00 K | $361.00 K |
| Dec 2016 | -$3.46 M | - | - |
FAQ
- What is Aquestive Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Aquestive Therapeutics?
- What is Aquestive Therapeutics annual EBIT year-on-year change?
- What is Aquestive Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Aquestive Therapeutics?
- What is Aquestive Therapeutics quarterly EBIT year-on-year change?
- What is Aquestive Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Aquestive Therapeutics?
- What is Aquestive Therapeutics TTM EBIT year-on-year change?
What is Aquestive Therapeutics annual earnings before interest & taxes?
The current annual EBIT of AQST is -$163.00 K
What is the all time high annual EBIT for Aquestive Therapeutics?
Aquestive Therapeutics all-time high annual earnings before interest & taxes is -$163.00 K
What is Aquestive Therapeutics annual EBIT year-on-year change?
Over the past year, AQST annual earnings before interest & taxes has changed by +$41.80 M (+99.61%)
What is Aquestive Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of AQST is -$7.31 M
What is the all time high quarterly EBIT for Aquestive Therapeutics?
Aquestive Therapeutics all-time high quarterly earnings before interest & taxes is $10.42 M
What is Aquestive Therapeutics quarterly EBIT year-on-year change?
Over the past year, AQST quarterly earnings before interest & taxes has changed by -$6.45 M (-747.16%)
What is Aquestive Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of AQST is -$19.26 M
What is the all time high TTM EBIT for Aquestive Therapeutics?
Aquestive Therapeutics all-time high TTM earnings before interest & taxes is $6.83 M
What is Aquestive Therapeutics TTM EBIT year-on-year change?
Over the past year, AQST TTM earnings before interest & taxes has changed by -$13.23 M (-219.15%)